Diabetic drug ACTOS (pioglitazone) have already had a stroke appears to protect people suffering another stroke, a new study finds.
Blood, medicine, and blood pressure and cholesterol, including Slim - - ACTOS with the standard treatment after a stroke reduced the odds of a stroke by 24 percent compared with a placebo, the researchers said. .
"ACTOS has had a stroke to help prevent a future stroke which represents a new option for patients," said lead researcher Dr. Walter Kernan, New Haven, who is professor of medicine at Yale School of Medicine said, .
For the study, Kernan and colleagues randomly assigned nearly 4,000 patients who had suffered a stroke or a mini stroke for the ACTOS or a placebo. None of the patients had diabetes but it is evidence of insulin resistance, putting at risk the blood sugar disease.
During the follow-up of almost five years, compared with about 12 percent of those receiving placebo 9% of those taking ACTOS, had a stroke or heart attack, researchers found.
Approximately 4% of those with diabetes developed to ACTOS, an almost 8 percent of the people showed, compared with studies taking into Placebo.
The report was published online Feb. 17 in the New England Journal of Medicine. The study also was scheduled to be presented Wednesday at the annual meeting in Los Angeles, American Stroke Association. Funding for the study was provided by the health institutions.
Does anyone knows how to prevent stroke ACTOS, said Kernan. Best guess drugs, reduces inflammation that improves insulin resistance, helps to regulate body fat and is "favorably affects the function of blood vessels," he said. "This could explain its effects on the recurrence of stroke and heart attack."
Insulin resistance can also play a role in risk for heart attack, said Kernan. "This trial is an important new target for the prevention of stroke provide strong evidence of insulin resistance," he said. "This trial takes preventive Neurology in a new direction and opens up new opportunities for patient care."
ACTOS may be used to prevent stroke, these results will depend on how they are determined by the medical community, said Kernan.
"ACTOS have had a stroke or mini-stroke, which can be an option for patients, but our conclusions about his character will emerge from a debate among scientists," he said.
Dr. Richard Libman New Hyde vice chairman of neurology at Long Island Jewish Medical Center in the park, N.Y. They can include the ability to stop this new finding many strokes, but it can be widely used drugs before to confirm.
"It improves insulin resistance which can reduce the risk of stroke or heart attack is the first study to show that treatment of patients with a drug," he said. "This is just one study, but it is forced to."
Dr. Gerald Bernstein in New York City's Lenox Hill Friedman Diabetes Institute, an endocrinologist at the hospital. "It is an upright look at a few thousand people in a reasonable period of ACTOS benefits and obligations," he said. "The question we all upside and no downside that we are left with is something that is not."
The drug was associated with some serious side effects. The study of people taking ACTOS, 10 pounds or more were more likely to receive surgery or hospitalization, the feet and ankles, broken bones and swelling, the researchers found.
A ACTOS may be a drug used to help prevent stroke, but this requires more knowledge before it can become a regular part of treatment of stroke, said Kernan.
For more information on stroke, visit the American Stroke Association Association.